A new drug for the treatment of type 2 diabetes has been approved by the U.S. Food and Drug Administration. Invokana (canaglifozin) has been put through a rigorous set of clinical trials, 9 to be exact that involved over 10,000 people. The trials showed improvements in blood glucose levels as hoped, by blocking glucose absorption by the kidney. The drug is not designed for type 1 diabetics, those with elevated ketones, people with kidney impairment or those with end stage renal disease.
They also recommend and should be the case for all care, the use of Invokana should be combined with proper diet and exercise. There are still more studies at this time for specific age groups, but one potential side-effect found was specific infections; more commonly vaginal yeast infection and urinary tract infections. Also, noted is the potential for a sudden drop in blood pressure when the patient stands up. For more information on Invokana, see Janssen Pharmaceuticals of Titusville, N.J.